Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 3/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.49 |
| ▸ | HINT1 | P49773 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1577230 | 1.00 | NT5E (0.57) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL12939473 | 1.00 | NT5E (0.57) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL12194800 | 1.00 | NT5E (0.57) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL15468735 | 1.00 | NT5E (0.57) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL18740412 | 0.96 | NT5E (0.53) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL723267 | 0.94 | NT5E (0.56) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL1576874 | 0.93 | TGM2 (0.59) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL13522449 | 0.93 | TGM2 (0.59) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| SCHEMBL10819892 | 0.93 | TGM2 (0.59) | NT5EPOLBIMPDH2TAS1R3TAS1R1 | |
| Inx-09114 SCHEMBL23319265 | 0.92 | P2RY2 (0.60) | NT5EPOLBIMPDH2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251487-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC | 2012-10-04 | — | — | US | disclosed |
| EP-2476690-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110243886-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | SURLERAUX DOMINIQUE | 2011-10-06 | — | — | US | disclosed |
| WO-2010014134-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARAMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243886-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, EIF2AK2 | NT5E 684/4885POLB 328/4885IMPDH2 479/4885 |
| US-20120251487-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, EIF2AK2 | NT5E 684/4885POLB 328/4885IMPDH2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.